Claritas Pharmaceuticals (CLAZF) Stock Statistics & Valuation Metrics

Claritas Pharmaceuticals has a market cap or net worth of $797.53K. The enterprise value is ―.

Claritas Pharmaceuticals has 37,786,587 shares outstanding. The number of shares has decreased by -2.65% in one year.

Claritas Pharmaceuticals’s return on equity (ROE) is 2.79 and return on invested capital (ROIC) is 482.39%.

The current PE Ratio of Claritas Pharmaceuticals is ―. Claritas Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Claritas Pharmaceuticals had revenue of 0.00 and earned 4.21M in profits. Earnings per share was 0.16.

In the last 12 months, operating cash flow was -953.00K and capital expenditures 0.00, giving a free cash flow of -953.00K billion.

Claritas Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Claritas Pharmaceuticals upcoming earnings date is ―, ―.

Claritas Pharmaceuticals as a current ratio of 0.14, with Debt / Equity ratio of 61.38%

In the past 12 months, Claritas Pharmaceuticals has paid -4.88M in taxes.

Claritas Pharmaceuticals EV to EBITDA ratio is -0.33, with an EV/FCF ratio of -3.02.

Claritas Pharmaceuticals has $2.00K in cash and marketable securities with $0.00 in debt, giving a net cash position of -$546.00K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Claritas Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―